ML-T7

ML-T7 is a potent Tim-3 inhibitor that blocks interactions with PtdSer and CEACAM1. It enhances the antitumor function of CTLs, CAR T cells, and NK cells in vitro and improves dendritic cell antigen presentation. This compound demonstrates efficacy in preclinical tumor models, supporting its investigation as a monotherapy or combined with checkpoint inhibitors like Nivolumab.